Introduction
Staphylococcus aureus is the leading cause of both healthcareassociated (HA) and community-associated (CA) infections. In the past decade, CA infections with MRSA have emerged throughout the world. CA-MRSA clones vary, and there are geographical differences among strains. The major CA-MRSA clone in Korea, ST72, with staphylococcal cassette chromosome mec (SCCmec) type IV (ST72-MRSA-IV), has distinct features, such as lack of PantonValentine leucocidin (PVL) genes in those that have spread throughout the Asian region or internationally. 1 Vancomycin has been the mainstay of treatment for patients with MRSA infections and thus reduced susceptibility to vancomycin is becoming a worldwide problem. Vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains are increasingly reported in MRSA strains throughout the world. 1, 2 With the exception of USA300, there have been few reports describing reduced susceptibility to vancomycin among CA-MRSA clones. 3 Vancomycin-resistant S. aureus (VRSA) strains have been shown to occur due to the transfer of the vanA gene from vancomycinresistant enterococci. 4 In VISA, on the other hand, the mechanism of reduced susceptibility to vancomycin is based on an accumulation of spontaneous chromosomal mutations: 5 SNPs in genes of two-component regulatory systems (vraSR, graRS and walKR), a gene encoding membrane proteins (yvqF), transcription regulators (agrA, agrC and rpoB), PBPs (pbp4 and pbpB) and a proteolytic regulatory gene (clpP). [5] [6] [7] [8] [9] [10] Although the mutations in these genes were identified in VISA strains of a limited number of genetic lineages, the molecular mechanisms of VISA and hVISA phenotypes may not be confined to strains with specific genetic backgrounds.
We previously reported the first case of a CA-ST72-MRSA-IV strain with vancomycin-intermediate resistance in Korea. In addition, ST72-MRSA-IV strains with reduced susceptibility to vancomycin and daptomycin were also described in Japan.
12 ST72 is a PVL-negative CA-MRSA clone identified specifically in Korea, 13 and it has recently become an important clone in hospitals, like the USA300 clone in the USA.
14 Reduced susceptibility to vancomycin in this clone would be of great concern. The present work aimed to investigate the genetic alterations that contribute to reduced susceptibility to vancomycin by tracking the mutations in ST72-MRSA-IV strains with reduced susceptibility to vancomycin using WGS and molecular techniques.
Materials and methods

Bacterial strains and plasmids
WGS drafts were obtained from a pair of vancomycin-susceptible S. aureus (VSSA) and VISA strains (VSSA303 and VISA072, respectively), which were isolated consecutively from a single patient, a 79-year-old man who experienced treatment failure with vancomycin and rifampicin during a 2 month period from August to November 2011. Both strains belonged to ST72, showing SCCmec type IV, agr group I and spa type t324, and were identical by PFGE. While the MICs of vancomycin and rifampicin for the VISA072 strain were 4 and !32 mg/L, those of VSSA303 were 1 and 0.06 mg/L, respectively. A detailed clinical history of the patient and preliminary characterization of the strains have been reported previously. 11 Bacterial strains and plasmids used in this study are listed in Table 1 . Staphylococcal strains were stored in glycerol broth at #80 C and normally subcultured twice onto a blood agar plate [Becton, Dickinson and Company (BD), NJ, USA] for 18-24 h before being used in an experiment. All S. aureus strains were routinely grown in brain heart infusion (BHI) broth (BD) and Escherichia coli was grown in LB broth or agar (BD). Chloramphenicol (12.5 mg/L) and ampicillin (100 mg/L) were used for the selection and maintenance of S. aureus and E. coli transformants, respectively.
Antimicrobial susceptibility testing
In vitro susceptibility testing was performed using the broth microdilution method according to the CLSI. 15 In vitro susceptibility to vancomycin, rifampicin, oxacillin, teicoplanin and daptomycin was tested. S. aureus ATCC 29213, Enterococcus faecium ATCC 29212 and E. coli ATCC 25922 were used as control strains. All tests were repeated with three independent cultures, each tested in duplicate.
WGS
To identify the genetic changes that confer the VISA phenotype, WGS of VSSA303 and VISA072 was completed using a next-generation sequencing technique. WGS was performed at Macrogen Inc. (Seoul, Korea) with Illumina Hiseq2000 Preliminary Performance Parameters. A total of 19 million and 24 million reads were generated for strains VSSA303 and VISA072, respectively. Paired-end read sequencing was performed with read lengths of 101 bp. Software BWA v0.5.9-r16 16 was used for assembly with the reference genome of S. aureus HL1 (GenBank accession number CP003979), which is a CA-MRSA strain of ST72, isolated in Korea. 17 Genetic alterations between the strain VSSA303 and VISA072, including SNPs and insertions and deletions (indels), were identified using SAMtools v0.1.18 (http://samtools.sourceforge.net/) and GATK v1.4.11 (http://www. broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit). The VISA phenotype-associated SNPs and indels identified by WGS comparison were confirmed by PCR amplification and sequencing of the PCR products. To predict whether the identified amino acid substitutions were likely to affect protein function, sorting intolerant from tolerant (SIFT) scores were Point mutations associated with vancomycin resistance in CA-MRSA-ST72 JAC calculated (http://sift.jcvi.org). Based on the amino acids appearing at each position, SIFT calculates the probability that an amino acid substitution at a position is tolerated, depending on the most frequent amino acid being tolerated. If the normalized value is ,0.05, the substitution is predicted to be deleterious.
18,19
Cloning, transformation and overexpression of target genes
The cloning and transformation of E. coli were performed using standard techniques. All restriction endonuclease and T4 DNA ligase (New England BioLabs, MA, USA) reactions were carried out according to the manufacturer's instructions. The mutated genes of S. aureus VISA072 were amplified using PCR with designed primers with restriction endonuclease SmaI sites (Table S1 , available as Supplementary data at JAC Online). All PCR fragment products were purified and ligated into a cloning site of E. coli-S. aureus shuttle vector pMK4. 20 These constructs were moved into E. coli DH5a, S. aureus RN4220 and the VSSA303 strain by electroporation, respectively. To improve transformation efficiency into the S. aureus strain, a modified electroporation method for S. aureus was performed as previously described. 21 Competent cells of S. aureus strain VSSA303 were concentrated to 1-3%10 cfu/mL. To test the impact on vancomycin susceptibility of the single-base mutations in each target gene, we overexpressed target genes cloned into pMK4 in a VSSA strain. All constructs were verified by both sequence and restriction enzyme analysis, followed by screening of successful transformants using a chloramphenicol marker on the pMK4 vector. To better understand the effect of each mutation on acquisition of reduced susceptibility to vancomycin, antimicrobial susceptibility testing, population analysis profile (PAP)/AUC analysis and transmission electron microscopy (TEM) were performed for WT and mutated strains.
Quantitative real-time RT-PCR (qRT-PCR)
vraSR mRNA expression was evaluated for VSSA303 and VISA072 under no vancomycin exposure and for VISA072 and a strain with a mutated vraR gene (S303-vraSR E127K ) under vancomycin exposure. RNA extraction for qRT-PCR was performed as previously described. 22 Total RNA was extracted using an RNeasy isolation kit (Qiagen); all RNA samples were analysed by A 260 /A 280 spectrophotometry and gel electrophoresis to assess concentration and integrity. qRT-PCR analysis was done using an AccuPower GreenStar qPCR Master mix (Bioneer, Daejeon, Korea) according to the manufacturer's protocol. Gene expression was compared according to threshold cycle (C T ) values converted into fold changes with respect to the reference strain (VSSA303, value " 1) using log 2 # (DDC T ). The change (n-fold) in the transcript level was calculated using the following equations:
The quantity of cDNA for each experimental gene was normalized to the quantity of 16S cDNA in each sample determined in a separate reaction. Each RNA sample was run in triplicate; values represent the means of at least three separate RNA samples.
Modified PAP/AUC
A modified PAP/AUC analysis was carried out according to the procedure described previously. 23 In brief, single colonies were inoculated in tryptic soy broth (TSB) and grown overnight at 37 C with shaking at 150 rpm. The bacterial solution was diluted with sterile saline to 10 #3 and 10
#5
. Aliquots of 100 lL of the diluted bacterial solution were spirally plated on BHI agar plates with the following concentrations of vancomycin: 0, 0.5, 1, 2, 3, 4, 6 and 8 mg/L. Colonies were counted after the plates had been incubated at 37 C for 48 h. PAP/AUC was calculated using Graphpad Prism 5.0 (Graphpad software, Inc., CA, USA). The AUC test /AUC Mu3 ratio was calculated and strains were categorized as VSSA, hVISA and VISA according to the ratio as follows: VSSA, ,0.9; hVISA, 0.9-1.3; and VISA, .1.3. Mu3 and Mu50 strains served as hVISA and VISA controls, respectively. 23 
TEM
The preparation of S. aureus cells for TEM was performed using standard procedures described previously. 24 Briefly, cells suspended in growth medium were fixed with an equal volume of 5% glutaraldehyde and stored for at least 24 h at 4 C until they were further processed for TEM. Thirty cells of each strain with nearly equatorial cut surfaces were measured for the evaluation of cell wall thickness.
Results
Non-synonymous mutations in the VISA strain (VISA072) compared with VSSA303
We sequenced and compared the whole genomes of VISA strain VISA072 and its susceptible, parental strain VSSA303. VISA072 and VSSA303 had a genome of 2753954 and 2756914 bp, respectively. We were able to map reads from the two strains to 98.3% and 98.1% of the S. aureus HL1 reference genome, respectively. The overall G ! C contents were 32.7% for both. Only five mutations (four SNPs and a deletion) were identified by comparison of genome sequence data, including rpoB (H481Y), dprA (G196C), femA (F92C), vraR (E127K) and a 64 bp deletion of agrC (E391stop) ( Table 2 ). All predicted mutations were non-synonymous and were further confirmed by PCR and sequencing. SIFT scores were calculated for four amino acid substitutions to predict whether these mutations affect protein function; all mutations were predicted to be deleterious (SIFT score ,0.05) ( Table 2) . A mutation in the dprA gene encoding DNA processing protein has not been identified previously as associated with antibiotic resistance. Even though mutations of vraR, agrC and femA genes have been found in the hVISA or VISA phenotype, the amino acid alterations detected in this study have not been identified. In the present study, we focused on the mutations in three genes (dprA, femA and vraR) to investigate the effect of genetic alterations on VSSA-to-VISA conversion.
Effect of genetic alterations on antibiotic susceptibility
To examine the functional influence of specific mutations found in the VISA strain, we cloned three mutated genes from VISA072, dprA (G169C), femA (F92C) and vraR (E127K), into multi-copy plasmid pMK4. Subsequently, the constructs were transformed into a vancomycin-susceptible clinical strain, VSSA303, and a vancomycin-susceptible laboratory strain, RN4220, by electroporation, generating transformed strains, designated S303-dprA G169C , S303-femA F92C , S303-vraR E127K , RN-dprA G169C , RN-femA F92C and RN-vraR E127K , respectively (Tables 1 and 2 ). Because the twocomponent regulatory system VraSR is co-transcribed and the components work together, we constructed a mutated vraR gene (vraR E127K ) alone (S303-vraR E127K and RN-vraR E127K ) and mutated vraR plus intact vraS (S303-vraSR E127K and RN-vraSR E127K ), respectively, to confirm the role of the two-component regulatory system in vancomycin resistance. Transformed strains with a mutated vraR gene, S303-vraR E127K and RN-vraR E127K , showed increased vancomycin MICs, compared with their parental strains VSSA303 and RN4220 (from 1 to 2 mg/L) ( Table 3) . Similar results were observed in S303-vraSR E127K and RN-vraSR E127K , in which the vraSR E127K operon was introduced (Table 3) . Simultaneously, the susceptibilities to teicoplanin of transformed strains with a mutated vraR gene also decreased (0.25 to 1 mg/L). However, Baek et al. no MIC changes were observed for the other transformed mutants with mutated dprA and femA genes. The introduction of a mutated femA gene into VSSA303 and RN4220 decreased the oxacillin MIC from 32 to 4 mg/L and from 0.12 to 0.06 mg/L, respectively, which was a phenomenon similar to that reported for other vraSR mutants in MRSA strains. 25 In addition, a decrease in oxacillin MIC from 32 to 8 mg/L was observed for S303-dprA G169C . The susceptibility to rifampicin of all transformants was not changed.
vraR mutation (E127K) confers acquisition of hVISA phenotype
To validate the impact on vancomycin susceptibility of the singlebase mutation in vraR (E127K), we performed qRT-PCR and population analysis. VISA072 exhibited overexpression of the vraSR regulon without respect to vancomycin exposure and both VISA072 and a strain with a mutated vraR gene (S303-vraSR E127K ) also showed vraSR mRNA overexpression under vancomycin exposure ( Figure 1 ). As shown in Figure 2 , all mutants with mutated vraR (S303-vraR E127K and RN-vraR E127K ) showed a typical hVISA curve, as seen in the Mu3 strain (Figure 2a) . Notably, similar results were observed in the RN4220 strain, indicating that mutated vraR (vraR E127K ) expression might not be effective in the limited physiological milieu of the VSSA cell to achieve an hVISA phenotype (Figure 2b) . Additionally, no differences were found between transformants with vraR E127K and vraSR E127K , which is consistent with the observation of vancomycin MICs (Table 3) .
Expression of mutated vraR (E127K) increases cell wall production
TEM revealed that S303-vraR E127K showed a remarkable change in cell wall thickness, compared with VISA072 and parental VSSA303 (Figure 3) . The cell wall thickening, which prevents the diffusion of vancomycin to its active site in the cytoplasmic membrane in the Significant difference in gene function as predicted by the SIFT score. MICs were determined using the broth microdilution method according to the CLSI. Relative fold change values of specific vraSR mRNAs are shown on the vertical axis; 16S rRNA was used as an internal control. VSSA303 was included as a reference strain (relative value " 1). *Significantly greater than strain VSSA303 (P , 0.05). The transcription level of VISA072 grown in the presence of vancomycin was significantly greater than that for VISA072 grown in the absence of vancomycin (P , 0.05). VAN, vancomycin. Point mutations associated with vancomycin resistance in CA-MRSA-ST72 JAC division septum, is one of the consistently observed features of hVISA or VISA strains. 26 The cell wall in S303-vraR E127K was thicker than that in the parental strain VSSA303, which might be due to the effect of vraR mutation on the cell wall. However, it was less thick than the phenotype observed in VISA072 strains, suggesting the existence of additional factors in the development of a full VISA phenotype.
Discussion
We tracked genetic alterations during the development of reduced susceptibility to vancomycin in a prevalent CA-MRSA clone in Korea, ST72-MRSA-IV. VISA or hVISA phenotypes have been reported mostly among HA-MRSA strains, rather than CA-MRSA strains, because selective pressure leading to vancomycin nonsusceptibility may be much greater in the hospital environment. Several studies showed that the PVL-negative community strain ST72-MRSA-IV accounted for a substantial proportion of HA infections in the hospitals, suggesting that CA-MRSA strains are emerging as major causes of HA infections in Korea.
14 Recently, ST72-MRSA-IV isolates that developed reduced susceptibility to key drugs, such as vancomycin and rifampicin, have been described. 11, 27 The genetic mechanism of reduced susceptibility to vancomycin in VISA and hVISA is still not understood fully. Diverse mutations in a small number of staphylococcal regulatory genes associated with reduced susceptibility to vancomycin have been experimentally proven to confer the resistance phenotype. 2 Herein, we identified five non-synonymous mutations by WGS analysis, including E127K in vraR, H481Y in rpoB, G196C in dprA, F92C in femA and a 64 bp deletion of agrC. Introduction of mutated vraR into the susceptible strains VSSA303 and RN4220 resulted in an increase in vancomycin MIC, suggesting that the vraR mutation E127K might influence VSSA-to-hVISA conversion regardless of genetic background. In addition, introduction of mutated vraR and vraSR showed the same elevated vancomycin MICs and results in PAP, implying that the effect of introduced vraR E127K was not dependent on the presence of VraS in the cell. The conformational change of the VraR protein by genetic alteration might have activated its response regulator function, independently of its signal transducer, VraS. A remarkable increase in cell wall thickness in the VSSA303 strain carrying a mutated vraR was also shown. Taking these results together, it is proposed that the genetic alteration vraR E127K may partially contribute to development of the VISA phenotype.
In addition to glycopeptides such as vancomycin and teicoplanin, the VISA072 strain developed non-susceptibility to rifampicin and daptomycin during treatment. Genetic alterations in VISA072 might contribute to the reduced susceptibility to these antibiotics. The rpoB gene encodes the RNA polymerase b-subunit and mutations in the rpoB gene, including H481Y in this study, are known to be exclusively associated with rifampicin resistance. 28 Recently, it has been reported that mutations in the rpoB gene might confer dual hetero-resistance to daptomycin and vancomycin in S. aureus and promote hVISA-to-VISA conversion of a strain Mu3. 6, 28 The agrc gene is an essential part of the quorumsensing agr locus in S. aureus, the 64 bp deletion in agrc gene (encoding sensory transduction histidine kinase) that created a stop codon at amino acid position 391, prematurely terminating agrc translation. Loss of function in agr has frequently been found in VISA strains. 29 The exact mechanism of how reduced agr expression affects reduced antibiotic susceptibility is not well known. Because the agr locus may be associated with other regulatory genes in S. aureus, it is speculated that changes in agr expression may invoke cell wall changes, as seen in VISA strains. The dysfunction of agr has been shown to reduce toxin release and virulence of S. aureus in a murine arthritis model. 30 Thus, increased Figure 3 . Cell wall thickness of S. aureus VSSA303, S303-vraR E127K and VISA072. Representative TEM revealed that S303-vraR E127K showed a remarkable change in cell wall thickness, compared with VISA072 and parental VSSA303, indicating the increased vancomycin MIC due to vraR mutation.
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vancomycin resistance may be linked to reduced virulence in S. aureus, although we did not investigate it. FemA is involved in the formation of UDP-N-acetylmuramoylpentapeptide, a staphylococcal cell wall precursor. 31 Although the introduction of an altered femA gene into VSSA strains did not change the vancomycin MIC, it might affect cell wall synthesis and partially contribute to the reduced susceptibility to vancomycin. 32 The femA gene and vraSR are well known as additional genetic determinants of the oxacillin resistance phenotype. 33 Thus, the genetic alteration in the femA gene may be associated partly with the change in oxacillin resistance.
Evolution to full VISA appears to be a step-wise process in many cases, where a number of unique and highly diverse mutations, each having an additional impact on resistance accumulation over time. 2 Although it was revealed that a mutation in the vraR gene mainly affected the development of the VISA phenotype in our strain, genetic alterations in the rpoB and agrC genes may potentially contribute to the reduced susceptibility to vancomycin. A recent study described four SNPs involved in reduced susceptibilities to vancomycin and daptomycin based upon complete genome data on the ST72 background. 12 Interestingly, there was no consistency with SNPs in our results, except a mutation in the rpoB gene, despite the same genetic background as that in our study, implying there are diverse paths to the acquisition of antibiotic resistance.
There are some limitations in our study. First, we transformed and overexpressed mutated genes in VSSA strains without knockout of the corresponding gene in recipients to examine the effect of alteration in VISA. Other factors might have affected increased vancomycin MIC. Second, the effect of mutation in the rpoB gene was not examined in this study, even though the genetic alteration of the gene was well known to confer vancomycin resistance. In addition, we did not identify the reversion of VISA to the VSSA phenotype by inactivating vraR. However, we aimed to explore the role of a mutation of the vraR gene in reduced vancomycin susceptibility in our VISA strain, not the role of the whole gene.
In summary, we identified five amino acid mutations potentially associated with reduced susceptibility to vancomycin using isogenic VSSA and VISA strains of ST72. In addition to mutations in the rpoB gene, a genetic alteration in the vraR gene, E127K, is revealed to contribute to the development of the VISA phenotype, which was supported by cell wall thickness and PAP analysis.
